View Older Stories View More Recent Stories

Jul 25, 2018 09:00AM PEOPLE and Great Place to Work® Name Horizon Pharma plc to 2018 “50 Companies That Care” List
Jul 16, 2018 08:33AM UPDATE: Horizon Pharma (HZNP) Announces USPTO Issuance of Additional Notices of Allowance With Claims Covering RAVICTI Oral Liquid
Jul 16, 2018 08:30AM Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of Additional Notices of Allowance With Claims Covering RAVICTI® (glycerol phenylbutyrate) Oral Liquid
Jul 9, 2018 08:30AM Horizon Pharma plc to Release Second-Quarter 2018 Financial Results and Host Webcast on August 8, 2018
Jun 15, 2018 05:45AM Horizon Pharma plc Presents Data at EULAR 2018 Advancing the Understanding and Management of Uncontrolled Gout
Jun 14, 2018 04:50AM Epidemiologic Study Findings Show 27 Percent Increase in Emergency Department Visits for Gout in the United States Over the Past Decade
Jun 4, 2018 08:00AM Horizon Pharma plc and the National Organization for Rare Disorders (NORD) Illustrate 35 years of Progress in Rare Disease at the Biotechnology Innovation Organization (BIO) International Convention
May 30, 2018 08:00AM Horizon Pharma plc to Participate in the Goldman Sachs 39th Annual Global Healthcare Conference
May 22, 2018 10:15AM Horizon Pharma plc Named One of the Best Small and Medium Workplaces in Chicago by FORTUNE
May 22, 2018 09:00AM Horizon Pharma plc Launches GoutRevealed.com to Spotlight the Journey and Stories of People Living with Uncontrolled Gout
May 9, 2018 07:00AM Horizon Pharma plc Reports Strong First-Quarter 2018 Orphan and Rheumatology Net Sales Growth; Increases Full-Year 2018 Guidance and Announces New Company Operating Structure to Enhance Focus on Rare
May 8, 2018 08:11AM National Health Partners (HPR) Announces USPTO Issuance of Additional Notices of Allowance With Claims Covering RAVICTI Oral Liquid
May 8, 2018 08:00AM Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of Additional Notices of Allowance With Claims Covering RAVICTI® (glycerol phenylbutyrate) Oral Liquid
May 4, 2018 08:00AM Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 3, 2018 08:00AM Horizon Pharma plc Announces Sangita Iyer as a 2018 Healthcare Businesswomen’s Association Rising Star
May 1, 2018 08:00AM Horizon Pharma plc to Participate in the UBS Global Healthcare Conference
Apr 12, 2018 04:30PM Horizon Pharma plc Named No. 1 Biopharma Company to Work for by Great Place to Work® and FORTUNE
Apr 9, 2018 08:00AM Horizon Pharma plc to Release First-Quarter 2018 Financial Results and Host Webcast on May 9, 2018
Apr 4, 2018 08:00AM Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Mar 6, 2018 04:05PM Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Feb 28, 2018 07:00AM Horizon Pharma plc Announces Fourth-Quarter and Full-Year 2017 Results
Feb 27, 2018 06:00PM Horizon Pharma plc Submits Supplemental New Drug Application for RAVICTI® (glycerol phenylbutyrate) Oral Liquid to Expand Age Range to Include Newborns
Feb 26, 2018 08:00AM Horizon Pharma Gift Establishes First Clinical Team Endowment at Children’s National Rare Disease Institute
Feb 26, 2018 07:00AM Horizon Pharma plc to Participate in the Cowen and Company 38th Annual Health Care Conference
Feb 22, 2018 09:00AM Horizon Pharma plc Announces Release of the First RAREis™ Song in Partnership with Sing Me a Story Foundation and Global Genes
Feb 6, 2018 04:05PM Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jan 30, 2018 08:30AM Horizon Pharma plc Announces the Launch of “Cystinosis United” to Educate, Inspire and Connect the Cystinosis Community
Jan 29, 2018 08:00AM Horizon Pharma plc to Release Fourth-Quarter and Full-Year 2017 Financial Results and Host Webcast on Feb. 28, 2018
Jan 8, 2018 07:25AM UPDATE: Horizon Pharma (HZNP) Reports Agreement to License Pre-Clinical Uricase Derivative (MEDI4945) from MedImmune
Jan 8, 2018 07:24AM Horizon Pharma (HZNP) Increases Peak Net Sales Guidance, Announces Rheumatology and Orphan Pipeline Developments
Jan 8, 2018 07:05AM Horizon Pharma plc Increases Peak Net Sales Guidance for Key Growth Drivers and Announces Rheumatology and Orphan Pipeline Developments
Jan 8, 2018 07:00AM Horizon Pharma plc Announces Agreement to License Pre-Clinical Uricase Derivative (MEDI4945) from MedImmune
Jan 5, 2018 04:05PM Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jan 4, 2018 07:30AM Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Dec 27, 2017 08:00AM Horizon Pharma plc Announces FDA Approval to Expand the Indication for PROCYSBI® (cysteamine bitartrate) Delayed-Release Capsules to Include Children One Year of Age and Older Living with Nephropathi
Dec 18, 2017 09:23AM Horizon Pharma plc to Present at the 36th Annual J.P. Morgan Healthcare Conference
Dec 5, 2017 04:05PM Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Nov 30, 2017 04:05PM Horizon Pharma plc to Participate in BMO Prescriptions for Success Healthcare Conference
Nov 30, 2017 06:00AM Horizon Pharma plc Names Shao-Lee Lin, M.D., Ph.D. Executive Vice President, Research and Development and Chief Scientific Officer
Nov 10, 2017 09:30AM Horizon Pharma plc Selected as One of Chicago’s Top Workplaces by the Chicago Tribune
Nov 7, 2017 04:05PM Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Nov 6, 2017 12:00PM Horizon Pharma plc Presents New Data at 2017 ACR/ARHP Annual Meeting, Advances Clinical Understanding of KRYSTEXXA® (pegloticase injection) in Adults with Uncontrolled Gout
Nov 6, 2017 07:00AM Horizon Pharma plc Announces Third-Quarter and Year-to-Date 2017 Results
Nov 4, 2017 11:00AM Horizon Pharma plc Presents Results from an Open-Label Study on the Use of PROCYSBI® (cysteamine bitartrate) Delayed-Release Capsules in Treatment-Naïve Children Younger than 6 Years of Age
Nov 3, 2017 11:02AM National Health Partners (HPR) Announces Poster Presentation on KRYSTEXXA at ASN
Nov 3, 2017 11:00AM Horizon Pharma plc Announces Poster Presentation on KRYSTEXXA® (pegloticase injection) at the American Society of Nephrology Kidney Week 2017
Nov 2, 2017 04:05PM Horizon Pharma plc to Participate in Investor Conferences in November
Oct 26, 2017 08:00AM Horizon Pharma plc Announces Availability of PROCYSBI™ (cysteamine bitartrate) in Canada
Oct 25, 2017 08:00AM Horizon Pharma plc Announces First Patient Enrolled in Confirmatory Phase 3 Clinical Trial Evaluating Teprotumumab for the Treatment of Moderate-to-Severe Active Thyroid Eye Disease
Oct 23, 2017 08:00AM Horizon Pharma plc to Present KRYSTEXXA® (pegloticase injection) Data for the Management of Uncontrolled Gout at the 2017 ACR/ARHP Annual Meeting
View More Recent Stories View Older Stories